3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Oct 31, 2024.
2 other insiders sold within 30 days.
Insider activity: Insider Song Lianyue sold about $709.7K of HFUS on Nov 26, 2024, the largest insider sale at the company on our record; 2 other insiders sold within 30 days.
2 earlier Form 4 trades (code P or S) here by this insider (1 buy, 1 sale), the last on Mar 19, 2024.
The trade is 92.2% of the 35,484,880 shares held after it.
2 other insiders sold within 30 days.
Insider activity: Insider Song Lianyue sold about $654.0K of HFUS on Oct 31, 2024, the largest insider sale at the company on our record; 2 other insiders sold within 30 days.
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM HFUS
FY Jul 2025
n/a
FY Jul 2024
n/a
FY Jul 2023
$561.3K
FY Jul 2022
$561.3K
FY Jul 2021
$553.5K
Apr 2026
$1.1M
Jan 2026
n/a
Oct 2025
$330.3K
Jul 2025
$178.1M
Apr 2025
$354.8K
Jan 2025
$29.1M
Oct 2024
$34.4M
Jul 2024
$98.2M
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM HFUS
FY Jul 2025
n/a
FY Jul 2024
n/a
FY Jul 2023
n/a
FY Jul 2022
n/a
FY Jul 2021
n/a
Apr 2026
+53.0%
Jan 2026
n/a
Oct 2025
+15.3%
Jul 2025
+0.4%
Apr 2025
+25.6%
Jan 2025
+0.5%
Oct 2024
+0.4%
Jul 2024
+1.1%
At each fiscal year end
Single quarter
Free cash flow, TTM
-$621.8K
operating cash flow minus capex, 2025-05-01 to 2026-04-30
Free cash flow, TTM HFUS
FY Jul 2025
-$158.1K
FY Jul 2024
$714.0K
FY Jul 2023
-$268.4K
FY Jul 2022
-$1.0M
FY Jul 2021
n/a
Apr 2026
n/a
Jan 2026
n/a
Oct 2025
n/a
Jul 2025
n/a
Apr 2025
n/a
Jan 2025
n/a
Oct 2024
n/a
Jul 2024
n/a
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity HFUS
FY Jul 2025
n/a
FY Jul 2024
n/a
FY Jul 2023
n/a
FY Jul 2022
n/a
FY Jul 2021
n/a
Apr 2026
n/a
Jan 2026
n/a
Oct 2025
n/a
Jul 2025
n/a
Apr 2025
n/a
Jan 2025
n/a
Oct 2024
n/a
Jul 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt HFUS
FY Jul 2025
n/a
FY Jul 2024
n/a
FY Jul 2023
n/a
FY Jul 2022
n/a
FY Jul 2021
n/a
Apr 2026
n/a
Jan 2026
n/a
Oct 2025
n/a
Jul 2025
n/a
Apr 2025
n/a
Jan 2025
n/a
Oct 2024
n/a
Jul 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity HFUS
FY Jul 2025
n/a
FY Jul 2024
n/a
FY Jul 2023
n/a
FY Jul 2022
n/a
FY Jul 2021
n/a
Apr 2026
n/a
Jan 2026
n/a
Oct 2025
n/a
Jul 2025
n/a
Apr 2025
n/a
Jan 2025
n/a
Oct 2024
n/a
Jul 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+41.6%
TTM net income over average of 2025-04-30 and 2026-04-30
Return on assets HFUS
FY Jul 2025
+20.7%
FY Jul 2024
+59.1%
FY Jul 2023
+17.5%
FY Jul 2022
-30.7%
FY Jul 2021
-37.5%
Apr 2026
+41.6%
Jan 2026
+31.7%
Oct 2025
+38.5%
Jul 2025
+20.7%
Apr 2025
+108.8%
Jan 2025
+141.2%
Oct 2024
+127.5%
Jul 2024
+59.1%
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
no debt line filed
Return on invested capital HFUS
FY Jul 2025
n/a
FY Jul 2024
n/a
FY Jul 2023
n/a
FY Jul 2022
n/a
FY Jul 2021
n/a
Apr 2026
n/a
Jan 2026
n/a
Oct 2025
n/a
Jul 2025
n/a
Apr 2025
n/a
Jan 2025
n/a
Oct 2024
n/a
Jul 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
capital employed is zero or negative
Return on capital employed HFUS
FY Jul 2025
n/a
FY Jul 2024
n/a
FY Jul 2023
n/a
FY Jul 2022
n/a
FY Jul 2021
-43.7%
Apr 2026
n/a
Jan 2026
n/a
Oct 2025
n/a
Jul 2025
n/a
Apr 2025
n/a
Jan 2025
n/a
Oct 2024
n/a
Jul 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
40.00x
close 2026-10-23 over four quarters of diluted EPS, 2025-05-01 to 2026-04-30
P/E, trailing HFUS
FY Jul 2025
100.00x
FY Jul 2024
111.00x
FY Jul 2023
n/a
FY Jul 2022
n/a
FY Jul 2021
n/a
Apr 2026
80.00x
Jan 2026
178.58x
Oct 2025
50.50x
Jul 2025
100.00x
Apr 2025
23.67x
Jan 2025
73.33x
Oct 2024
97.54x
Jul 2024
111.00x
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value HFUS
FY Jul 2025
n/a
FY Jul 2024
n/a
FY Jul 2023
n/a
FY Jul 2022
n/a
FY Jul 2021
n/a
Apr 2026
n/a
Jan 2026
n/a
Oct 2025
n/a
Jul 2025
n/a
Apr 2025
n/a
Jan 2025
n/a
Oct 2024
n/a
Jul 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-1.2%
TTM free cash flow over market value at close 2026-10-23
FCF yield HFUS
FY Jul 2025
-0.1%
FY Jul 2024
+0.2%
FY Jul 2023
-0.1%
FY Jul 2022
-1.6%
FY Jul 2021
n/a
Apr 2026
-0.6%
Jan 2026
-0.4%
Oct 2025
-1.4%
Jul 2025
-0.1%
Apr 2025
+0.6%
Jan 2025
+0.2%
Oct 2024
+0.2%
Jul 2024
+0.2%
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing EPS growth -17%, PEG needs growth
PEG, trailing HFUS
FY Jul 2025
4.00x
FY Jul 2024
n/a
FY Jul 2023
n/a
FY Jul 2022
n/a
FY Jul 2021
n/a
Apr 2026
n/a
Jan 2026
n/a
Oct 2025
n/a
Jul 2025
4.00x
Apr 2025
n/a
Jan 2025
n/a
Oct 2024
n/a
Jul 2024
n/a
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-23. Hover or tap a tile for its yearly and quarterly history.Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
Revenue growth, YoY+185.3% · 92 pct, sector of 480
Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Risk and compliance
100
Inputs
Short interest, % of float+0.0% · 100 pct, sector of 530
Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
5 not measured: Profitability, Financial health, Insider conviction, Institutional and government, US patents
Profitability needs 2 of 4 inputs, 1 present: average equity is zero or negative; capital employed is zero or negative; no debt line filed
Financial health needs 1 of 2 inputs, 0 present: no debt line filed
Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
Institutional and government needs 1 of 4 inputs, 0 present: fewer than five funds report holding it; no Congress trades in 365 days; no federal contracts in 180 days; no lobbying filings in the last four quarters
US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet
2 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
No password to create and no card required. We store your email address, your watchlist and your preferences, nothing else.
PRIVACY & COOKIES
We track filings, not you.
Essential cookies keep you signed in and remember this choice.
Google Analytics 4 and Microsoft Clarity load only if you allow them here; they
count visits and record how pages are used. We run no advertising and never sell
data. Details in the privacy policy. Change this any time
via "Cookie settings" in the footer.